References
- 1. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol 2002; 20: 221-30.
- 2. Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F, et al. Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15: 528-34.
- 3. Radman I, Basić N, Labar B, Kovacević J, Aurer I, Bogdanić V, et al. Long-term results of conventional-dose salvage chemotherapy in patients with refractory and relapsed Hodgkin’s disease (Croatian experience). Ann Oncol 2002; 13: 1650-5.
- 4. Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5: 27-37.
- 5. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-84.
- 6. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008; 141: 3-13.
- 7. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005; 106: 1473-8.
- 8. Czyz J, Szydlo R, Knopinska-Posluszny W, Hellmann A, Gozdzik J, Hansz J, et al. Treatment for primary refractory Hodgkin’s disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy. Bone Marrow Transplant 2004; 33: 1225-9.
- 9. Morabito F, Stelitano C, Luminari S, Mammi C, Marcheselli L, Callea V, et al. The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin’s lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Bone Marrow Transplant 2006; 37: 283-8.
- 10. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin’s lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant 2013; 19: 410-7.
- 11. Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, et al. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin’s lymphoma. Bone Marrow Transplant 2004; 33: 1015-23.
- 12. Puig N, Pintilie M, Seshadri T, Al-Farsi K, Nagy T, Franke N, et al. Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin’s lymphoma. Haematologica 2010; 95: 1496-502.
- 13. Castagna L, Bramanti S, Balzarotti M, Sarina B, Todisco E, Anastasia A, et al. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol 2009; 145: 369-72.
- 14. Collins GP, Parker AN, Pocock C, Kayani I, Sureda A, Illidge T, et al. Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma. Br J Haematol 2014; 164: 39-52.
- 15. The National Comprehensive Cancer Network. NCCN Guidelines. [citated 2015 Jul 6]. Available at http://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf.
- 16. Thomson KJ, Peggs KS, Blundell E, Goldstone AH, Linch DC. A second autologous transplant may be efficacious in selected patients with Hodgkin’s lymphoma relapsing after a previous autograft. Leuk Lymphoma 2007; 48: 881-4.
- 17. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012; 30: 2183-9.
- 18. Devizzi L, Santoro A, Bonfante V, Viviani S, Balzarini L, Valagussa P, Bonadonna G. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin’s disease. Ann Oncol 1994; 5: 817-20.
- 19. Moskowitz AJ, Hamlin PA Jr, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013; 31: 456-60.
- 20. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, et al. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 2012; 119: 4123-8.
- 21. Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B, et al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood 2012; 119: 4129-32.
- 22. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85: 320-4.
- 23. Venkatesh H, Di Bella N, Flynn TP, Vellek MJ, Boehm KA, Asmar L. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin’s lymphoma. Clin Lymphoma 2004; 5: 110-5.
- 24. Provencio M, Sánchez A, Sánchez-Beato M. New drugs and targeted treatments in Hodgkin’s lymphoma. Cancer Treat Rev 2014; 40: 457-64.
- 25. Kharfan-Dabaja MA, Hamadani M, Sibai H, Savani BN. Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! Bone Marrow Transplant 2014; 49: 599-606.
- 26. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012; 30: 2197-203.
- 27. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015; 372: 311-9.
- 28. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010; 16: 888-97.
- 29. eMC. Adcetris 50 mg powder for concentrate for solution for infusion. [citated 2015 Jul 6]. Available at https://www.medicines.org.uk/emc/medicine/27173.
- 30. Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012; 119: 6379-81.
- 31. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-21.
- 32. Gopal AK, Ramchandren R, O’Connor OA, Berryman RB, Advani RH, Chen R, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012; 120: 560-8.
- 33. Rothe A, Sasse S, Goergen H, Eichenauer DA, Lohri A, Jäger U, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood 2012; 120: 1470-2.
- 34. Forero-Torres A, Fanale M, Advani R, Bartlett NL, Rosenblatt JD, Kennedy DA, Younes A. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies. Oncologist 2012; 17: 1073-80.
- 35. Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, Radford J. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica 2013; 98: 611-4.
- 36. Zinzani PL, Viviani S, Anastasia A, Vitolo U, Luminari S, Zaja F, et al. Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica 2013; 98: 1232-6.
- 37. Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, et al. A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. Clin Cancer Res 2012; 18: 248-55.
- 38. Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015; 125: 1236-43.
- 39. Rothe A, Sasse S, Goergen H, Eichenauer DA, Lohri A, Jäger U, et al. Brentuximab vedotin (SGN-35) in patients with relapsed/refractory CD30-positive hematologic malignancies without prior high-dose chemotherapy and stem cell transplantation. [ASH Annual Meeting Abstracts]. Blood 2012; 120: Abstract 2743.
- 40. Younes A, Connors JM, Park SI, Fanale M, O’Meara MM, Hunder NN, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol 2013; 14: 1348-56.
- 41. Wagner-Johnston ND, Bartlett NL, Cashen A, Berger JR. Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma 2012; 53: 2283-6.
- 42. Jalan P, Mahajan A, Pandav V, Bekker S, Koirala J. Brentuximab associated progressive multifocal leukoencephalopathy. Clin Neurol Neurosurg 2012; 114: 1335-7.
- 43. Urru SA, Mariotti E, Carta P, Massidda S, Marcias M, Murru R, et al. Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: a case report. Drugs R D 2014; 14: 9-11.